Literature DB >> 2783182

Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.

S A Said1, A M Foda.   

Abstract

The influence of cimetidine on piroxicam plasma levels and pharmacokinetic parameters was studied in both rats and healthy volunteers. In male rats, intravenous injection of piroxicam (6 mg/kg) in animals pretreated with cimetidine (50 mg/kg intramuscular) resulted in plasma piroxicam concentrations significantly higher than those of animals which received piroxicam alone. The plasma half-life (1/2) of piroxicam in male rats was about 8.3 h and it was increased to 20.74 h by cimetidine pretreatment. The mean area under piroxicam plasma level-time curves was significantly (p less than 0.01) higher in case of rats pretreated with cimetidine compared with those treated with piroxicam alone. Similar results were obtained in male healthy volunteers, where administration of a single dose of piroxicam (20 mg orally) to subjects who received cimetidine (200 mg 3 times a day orally) resulted in plasma piroxicam concentrations significantly higher than those of subjects treated with piroxicam alone. The t1/2 of piroxicam was increased from 37.36 to 52.86 h with cimetidine administration. Also the mean area under piroxicam plasma level-time curves was significantly (p less than 0.05) increased by cimetidine administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783182

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

1.  Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations.

Authors:  Vimon Tantishaiyakul; Krit Suknuntha; Visit Vao-Soongnern
Journal:  AAPS PharmSciTech       Date:  2010-05-29       Impact factor: 3.246

Review 2.  Interactions between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues.

Authors:  J S Dixon; M C Page
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures.

Authors:  Vimon Tantishaiyakul; Sarunyoo Songkro; Krit Suknuntha; Pattakarn Permkum; Pattawee Pipatwarakul
Journal:  AAPS PharmSciTech       Date:  2009-06-12       Impact factor: 3.246

4.  A lack of pharmacokinetic interaction between ranitidine and piroxicam.

Authors:  J S Dixon; L F Lacey; M E Pickup; S J Langley; M C Page
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 6.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

7.  Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats.

Authors:  A Mukherjee; V G Hale; O Borga; R Stein
Journal:  Inflamm Res       Date:  1996-11       Impact factor: 4.575

8.  Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Authors:  Chang-Keun Cho; Pureum Kang; Hye-Jung Park; Eunvin Ko; Chou Yen Mu; Yun Jeong Lee; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-05-31       Impact factor: 4.946

Review 9.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 10.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.